Teva Pharmaceutical Industries Investor Presentation — January 2022

Document content

Teva Pharmaceutical Industries Ltd.

J.P. Morgan Healthcare Conference

President & CEOJanuary 11, 2022| 2 |Cautionary Note Regarding Forward-Looking Statements

This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, which are based o n management’s current beliefs and expectations and are subject to substantial risks and

uncertainties, both known and unknown, that could cause our future results , performance or achievements to differ significantly from that expresse d or implied by such forward-looking statements. Important factors that could cause or

contribute to such differences include risks relating to:

• our ability to successfully compete in the marketplace, including: that we are substantially dependent on our generic products; consolidation of ou r customer base and commercial alliances among our customers; delays in launches of

new generic products; the increase in the number of competitors targeting g eneric opportunities and seeking U.S. market exclusivity for generic ver sions of significant products; our ab ility to develop and commercialize

biopharmaceutical products; competition for our specialty products, including AUSTEDO®, AJOVY® and COPAXONE®; our ability to achieve expected re sults from investments in our product pipeline; our ability to develop and

commercialize additional pharmaceutical produc ts; and the effectiveness of our patents and other m easures to protect our intellectual property ri ghts;

• our substantial indebtedness, which may limit our ability to incur additional indebtedness, engage in additional transactions or make new investme nts, may result in a further downgrade of our credit ratings; and our inability to raise

debt or borrow funds in amounts or on terms that are favorable to us;

• our business and operations in general, including: uncertainty regarding t he COVID-19 pandemic and its impact on our business, financial condition , operations, cash flows, and liquidity and on the economy in general; our ability to

successfully execute and maintain the activities and efforts related to th em e a s u r e sw eh a v et a k e no rm a yt a k ei nr e s p o n s et ot h eC O V I D -1 9p a n d e m i ca n d associated costs therewith; effectiveness of our optimization efforts; our ability

to attract, hire and retain highly skilled personnel; manufacturing or quality control problems; interruptions in our supply chain; disruptions of information technology systems; breaches of ou r data security; variations in intellectual

property laws; challenges associated with conduc ting business globally, including political or e conomic instability, major hostilities or terro rism; costs and delays resulting from the exten sive pharmaceutical regulation to which we are